| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | LNCR2; PAOD2; NACHRA3 |
| Entrez GeneID | 1136 |
| clone | 6D3A10 |
| WB Predicted band size | 57.5kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CHRNA3 (AA: 32-240) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD79A抗体的3篇代表性文献的简要信息(注：文献标题和作者为示例性内容，建议通过学术数据库核实具体文献)：
---
1. **"CD79A: A key component of the B-cell receptor signaling machinery"**
*作者：Küppers, R., et al. (2002)*
**摘要**：该研究阐述了CD79A作为B细胞受体(BCR)复合物的重要组成部分，在B细胞发育和信号转导中的核心作用。作者通过基因敲除实验证明，CD79A缺失会导致BCR组装异常和B细胞功能缺陷。
---
2. **"Mutations in CD79A and CD79B in diffuse large B-cell lymphoma"**
*作者：Davis, R.E., et al. (2010)*
**摘要**：本文分析了弥漫大B细胞淋巴瘤(DLBCL)中CD79A和CD79B的基因突变，发现CD79A的酪氨酸磷酸化位点突变可能影响BCR信号通路，并与肿瘤细胞存活及耐药性相关。
---
3. **"Targeting CD79A with monoclonal antibodies for B-cell malignancy therapy"**
*作者：Cragg, M.S., et al. (2018)*
**摘要**：研究开发了一种针对CD79A胞外域的单克隆抗体，并在体外和小鼠模型中验证了其通过诱导BCR内吞和阻断下游信号通路抑制B细胞恶性肿瘤增殖的效果。
---
4. **"CD79A as a diagnostic marker in B-cell lineage classification"**
*作者：Stevenson, F.K., et al. (2005)*
**摘要**：探讨了CD79A抗体在临床病理诊断中的应用，证实其作为B细胞特异性标记物在区分B细胞淋巴瘤与其他类型肿瘤中的高敏感性和特异性。
---
**提示**：实际文献需通过PubMed、Web of Science等平台检索，建议结合关键词“CD79A antibody”、“BCR signaling”或“B-cell lymphoma”获取最新研究。
The CD79a antibody targets the CD79a protein, a critical component of the B-cell receptor (BCR) complex. CD79a, also known as Igα, pairs with CD79b (Igβ) to form a heterodimer that non-covalently associates with surface immunoglobulins, enabling BCR signal transduction. This signaling is essential for B-cell development, antigen recognition, and immune response modulation. Structurally, CD79a contains extracellular, transmembrane, and cytoplasmic domains, with its cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM) initiating downstream signaling cascades upon antigen binding.
CD79a antibodies are widely used in research and diagnostics to identify B-cell lineages, particularly in malignancies like B-cell lymphomas, leukemias, and multiple myeloma. In clinical pathology, CD79a immunohistochemistry (IHC) helps distinguish B-cell neoplasms from T-cell or myeloid malignancies. The antibody’s specificity for normal and neoplastic B-cells makes it valuable for classifying hematopoietic tumors and monitoring minimal residual disease.
Therapeutically, CD79a has been explored as a target for antibody-drug conjugates (ADCs) and bispecific antibodies in treating B-cell disorders. For example, therapies targeting CD79a aim to deliver cytotoxic agents directly to malignant B-cells while sparing healthy tissues. Mutations in CD79a are also linked to immunodeficiency disorders, underscoring its role in immune function. Overall, CD79a antibodies serve as vital tools in understanding B-cell biology and advancing diagnostic and therapeutic strategies in hematologic diseases.
×
